This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Hayne, D. et al. The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer. BJU Int. https://doi.org/10.1111/bju.16325 (2024)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Masone, M.C. Safe delivery of ICI therapy through sub-urothelial injection. Nat Rev Urol (2024). https://doi.org/10.1038/s41585-024-00884-w
Published:
DOI: https://doi.org/10.1038/s41585-024-00884-w